DaVita HealthCare Partners (NYSE:DVA) was upgraded by equities researchers at Raymond James Financial from an “outperform” rating to a “strong-buy” rating in a report issued on Thursday.

Other analysts also recently issued reports about the company. KeyCorp reiterated a “hold” rating on shares of DaVita HealthCare Partners in a research report on Wednesday. Wolfe Research upgraded DaVita HealthCare Partners from a “market perform” rating to an “outperform” rating in a research report on Monday, October 23rd. Bank of America decreased their target price on DaVita HealthCare Partners from $75.00 to $66.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 8th. Zacks Investment Research downgraded DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Finally, SunTrust Banks set a $57.00 price objective on DaVita HealthCare Partners and gave the company a “hold” rating in a research report on Sunday, October 15th. Four investment analysts have rated the stock with a sell rating, six have given a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $63.00.

Shares of DaVita HealthCare Partners (DVA) opened at $69.20 on Thursday. The company has a current ratio of 1.40, a quick ratio of 1.35 and a debt-to-equity ratio of 1.79. The company has a market capitalization of $11,529.89, a price-to-earnings ratio of 17.41, a price-to-earnings-growth ratio of 12.28 and a beta of 0.97. DaVita HealthCare Partners has a 12-month low of $52.51 and a 12-month high of $70.16.

DaVita HealthCare Partners (NYSE:DVA) last posted its earnings results on Tuesday, November 7th. The company reported $0.81 EPS for the quarter, missing the Zacks’ consensus estimate of $0.94 by ($0.13). The firm had revenue of $3.92 billion for the quarter, compared to analysts’ expectations of $3.91 billion. DaVita HealthCare Partners had a return on equity of 13.31% and a net margin of 3.40%. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.95 earnings per share. equities analysts predict that DaVita HealthCare Partners will post 3.42 EPS for the current year.

DaVita HealthCare Partners announced that its Board of Directors has initiated a stock buyback plan on Tuesday, October 10th that authorizes the company to repurchase $1.50 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.

Several large investors have recently modified their holdings of the company. California Public Employees Retirement System lifted its position in shares of DaVita HealthCare Partners by 1.9% in the third quarter. California Public Employees Retirement System now owns 490,132 shares of the company’s stock valued at $29,109,000 after acquiring an additional 9,332 shares in the last quarter. Canada Pension Plan Investment Board increased its stake in DaVita HealthCare Partners by 14.7% in the third quarter. Canada Pension Plan Investment Board now owns 444,358 shares of the company’s stock valued at $26,390,000 after purchasing an additional 56,988 shares during the last quarter. Schroder Investment Management Group increased its stake in DaVita HealthCare Partners by 769.0% in the third quarter. Schroder Investment Management Group now owns 434,191 shares of the company’s stock valued at $25,387,000 after purchasing an additional 384,224 shares during the last quarter. Speece Thorson Capital Group Inc. increased its stake in DaVita HealthCare Partners by 14.5% in the third quarter. Speece Thorson Capital Group Inc. now owns 321,182 shares of the company’s stock valued at $19,075,000 after purchasing an additional 40,667 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in DaVita HealthCare Partners by 4.4% in the third quarter. Rhumbline Advisers now owns 321,155 shares of the company’s stock valued at $19,073,000 after purchasing an additional 13,471 shares during the last quarter. Institutional investors and hedge funds own 85.32% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was first reported by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://www.americanbankingnews.com/2017/12/07/davita-healthcare-partners-dva-rating-increased-to-strong-buy-at-raymond-james-financial.html.

About DaVita HealthCare Partners

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Analyst Recommendations for DaVita HealthCare Partners (NYSE:DVA)

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.